Source: Annual Congress 2008 - Asthma and inhalation injuries at work
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
D. Talini, F. Novelli, A. D. Vellore, L. Malagrinò, L. Melosini, S. Burge, P. L. Paggiaro (Pisa, Italy; Birmingham, United Kingdom). Sputum eosinophilia and FEV1 decline in occupational asthma. Eur Respir J 2008; 32: Suppl. 52, 3198

Member's Comments

No comment yet.

Related content which might interest you: FEV1 decline and eosinophilia in occupational asthma Source: Annual Congress 2011 - The work environment in the clinic Year: 2011 Rate of FEV1 decline in workers with eosinophilic and non-eosinophilic occupational asthma Source: Eur Respir J 2007; 30: Suppl. 51, 155s Year: 2007 FEV1 decline in occupational asthma Source: Eur Respir J 2003; 22: Suppl. 45, 488s Year: 2003 Sputum neutrophilia and annual decline of FEV1 in dust exposed workers Source: Annual Congress 2011 - Environmental exposure and disease mechanisms Year: 2011 Sputum bacteriology in acute COPD exacerbations: correlation with FEV1 deterioration Source: Eur Respir J 2001; 18: Suppl. 33, 189s Year: 2001 Sputum eosinophilia vs exhaled NO as markers of airways inflammation in asthma: relationship with asthma control Source: Eur Respir J 2005; 26: Suppl. 49, 736s Year: 2005 Predictors of sputum eosinophilia in severe asthma Source: Virtual Congress 2020 – Clinical parameters in severe asthma Year: 2020 Predictive value of sputum eosinophilia for the rapid decline of FEV1 after a three-day withdrawal of therapy in asthmatic subjects Source: Eur Respir J 2001; 18: Suppl. 33, 335s Year: 2001 Sputum eosinophilia, airway hyperresponsiveness and airway narrowing in young adults with former asthma Source: Eur Respir J 2005; 26: Suppl. 49, 733s Year: 2005 Baseline FEV1and sputum neutrophils and macrophages predict the decrease in FEV1 after inhaled corticosteroid withdrawal in COPD Source: Eur Respir J 2004; 24: Suppl. 48, 306s Year: 2004 Induced sputum and airway inflammation in asthma and COPD Source: Annual Congress 2006 - PG14 - Noninvasive monitoring of asthma inflammation and treatment Year: 2006 Reducing the decline of FEV1 after a 4-year therapy with montelukast in patients with bronchial asthma Source: Annual Congress 2008 - Recent advances in the pathogenesis and treatment of asthma and COPD Year: 2008 eNO, ECP and bronchial hyperresponsiveness in mild asthmatic children out of therapy Source: Eur Respir J 2005; 26: Suppl. 49, 42s Year: 2005 Patterns of bronchodilator reversibility of FEV1 in asthma and COPD patients Source: Annual Congress 2012 - Translational respiratory medicine in asthma and COPD Year: 2012 Sputum eosinophils and bronchial hyperreactivity in patients with chronic cough Source: Eur Respir J 2005; 26: Suppl. 49, 479s Year: 2005 Cysteinyl-leukotriene levels in sputum differentiate asthma from rhinitis patients with or without bronchial hyperresponsiveness Source: Annual Congress 2007 - Asthma subphenotypes Year: 2007 Bronchial hyperresponsiveness to methacholine and exercise, relation to allergy in asthma patients Source: Eur Respir J 2002; 20: Suppl. 38, 504s Year: 2002 Small airways disease and peripheral eosinophilia predict airway hyperresponsiveness in Irish patients with suspected asthma Source: International Congress 2015 – Is asthma always an easy disease to diagnose and manage? Year: 2015 Monitoring of sputum eosinophils in long-term treatment of bronchial asthma Source: Eur Respir J 2002; 20: Suppl. 38, 111s Year: 2002 Asthma and persistent low sputum eosinophilia Source: Annual Congress 2009 - Airway inflammation and asthma control Year: 2009